Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28...
-
Upload
roland-elliott -
Category
Documents
-
view
217 -
download
0
Transcript of Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28...
![Page 1: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/1.jpg)
1
www.tfda.or.tz
Training Course for Introducing Pharmacovigilance of HIV Medicines:
November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.
TANZANIA PHARMACOVIGILANCE ACTIVITES AND PLANS :
Henry IrundeTanzania Food and Drugs Authority
![Page 2: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/2.jpg)
2
www.tfda.or.tz
Map of Tanzania
2nd largest lakeworldwide
2nd deepest lakeworldwide
Highest Mt.in Africa
![Page 3: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/3.jpg)
3
www.tfda.or.tz
Country profile I
• Total area of country: 945,000 sq. Km
• Approx. 40 millions population
• Approx. 5000 doctors, 12,000 nurses and 900 pharmacists
• GDP per capita: $800 est.
![Page 4: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/4.jpg)
4
www.tfda.or.tz
Country profile II
• Diseases of public health importance include Malaria, HIV/AIDS & TB
• HIV/AIDS prevalence: 7.0% est.
• Life expectancy at birth 44.6yrs est.
• Birth rate 39.5/1000 population est.
• Death rate 17.4/1000 population est.
![Page 5: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/5.jpg)
5
www.tfda.or.tz
ART Program:
• By the year 2003 a total of 176,102 AIDS cases were reported to NACP from the 21 regions
• In 2007 about 2 million persons were estimated to be living with HIV and AIDS
• Approximated 600,000 (30%) were in need of ART.
• To date 407,716 are on care and 205, 879 on ART (June, 2009) and over 60% are women
![Page 6: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/6.jpg)
6
www.tfda.or.tz
1st line treatment regimens
![Page 7: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/7.jpg)
7
www.tfda.or.tz
First line treatment regimens
• Zidovudine(AZT)+Lamivudine(3TC)+Nevirapine (NVP)/or EFV
• Stavudine(d4T)+Lamivudine(3TC)+Efavirenz (EFV)/or NVP
• Tenofovir (TDF) + Emtricitabine (FTC) + Efavirenz (EFV)/or NVP
• Tenofovir (TDF) + Lamuvidine (3TC) + Efavirenz (EFV)
• Tenofovir (TDF) + Lamuvidine (3TC) + Nevirapine (NVP)
![Page 8: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/8.jpg)
8
www.tfda.or.tz
2ND Line treatment regimens
• TDF plus 3TC or FTC combined with a ritonavir-boosted PI, either LPV/r or ATV/r (TDF+3TC or FTC +LPV/r or ATV/r)
• ABC plus ddI combined with a ritonavir-boosted PI, either LPV/r or ATV/r (ABC + ddI + LPV/r or ATV/r)
• The second line NRTI choice for adults and adolescents depends on the first line regimen
• Note that LPV/r , TDF/3TC and TDF/FTC are currently available as FDC formulations which simplify dosing
![Page 9: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/9.jpg)
9
www.tfda.or.tz
Country PV background info
• 1989 A Drug Information Centre (TADATIS) was established at MMC now MNH funded by WHO and DANIDA
• Objectives were to monitor ADRs and promote rational use of medicines,
• A spontaneous (yellow form) system of capturing ADRs was established
• 1993 Tanzania officially became member of WHO International Drug Monitoring program.
![Page 10: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/10.jpg)
10
www.tfda.or.tz
Current Country development
• 2003 TFDA was established and empowered by law to ensure quality, safety and effectiveness of drugs.
• TFDA mission statement is to protect the public health by ensuring availability of safe, quality and efficacy of food, drugs, cosmetics and medical devices
• TFDA is responsible for Marketing Authorization of
medicines for use and Post-marketing risk analysis
![Page 11: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/11.jpg)
11
www.tfda.or.tz
Current developments cont….• Established PV system and implementation of
ADR Monitoring is under Clinical trials and pharmacovigilance department
• Zone Drug Information Centers at MNH, Bugando, KCMC and Mbeya referral hospital were established
• Collaboration with stakeholders such as PHPs & NGOs e.g MSH, AIDS Relief/CRS, INESS, IHI.
• Integrating Pharmacovigilance in PHPs
![Page 12: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/12.jpg)
12
www.tfda.or.tz
WHO Collaborating Centre for Drug Monitoring
DRUG SAFETY MONITORING BY THE TFDA
Pharmaceutical industry
KilimanjaroKCMC
MbeyaMRH
MuhimbiliMNH
BugandoBMC
PATIENT HEALTH PROFESSIONNALS
![Page 13: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/13.jpg)
13
www.tfda.or.tz
Integrating PV in PHPs
PHP opportunity to implement
PV activities Offer a cohort of patients
under controlled conditions to be monitored for safety over a period of time
PV
detect , evaluate, and prevent adverse events
promote rational use of drugs in mass treatment programmes
Evaluate the impact of the programmes
improve acceptability of the programme
![Page 14: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/14.jpg)
14
www.tfda.or.tz
Expert Safety Review Panel
INTEGRATING P.H.P AND PVFUNCTIONAL AND STRUCTURAL RELATIONSHIP
W.H.OPROGRAMME
S
W.H.OPROGRAMME
S
V a c c i n e sM a l a r i a
T u b e r c u l o s i sF i l a r i a s i s
T r a c h o m a t i s
WHO ADVISORYCOMMITEE
WHO-PV(UMC)
PV CoordinatorNational PV centre
Health workers
NATIONAL PUBLIC HEALTH PROGRAMMES
V a c c i n e sM a l a r i a
T u b e r c u l o s i sF i l a r i a s i s
T r a c h o m a t i s
DISTRICT INVESTIGATION
TEAM
DRUG REGULATORY AUTHORITY
PATIENTS
PATIENTS
![Page 15: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/15.jpg)
15
www.tfda.or.tz
Current development cont……..• Strengthen previous yellow form system (spontaneous)
more HCW sensitization, Swahili version yellow form was produced
• Introducing new innovation methods of monitoring
medicine safety such Cohort Event Monitoring (CEM)
• Introducing the use of modern data management tools such as Vigiflow for spontaneous data and CEMflow for CEM data
![Page 16: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/16.jpg)
16
www.tfda.or.tz
Reports of Suspected ADRs from ARVs (June 06, to Nov
2009) SOC as per Vigiflow analysis. Skin & appendages (eczema, pruritis, rash, rash maculor papular, urticaria, fixed eruption, SJs)
60 (37.74%)
Centr & periph nervous system disorders 35 (22.00%)
Liver and biliary system disorders 3 ( 2.00%)
Gastro-intestinal system disorders 19 (11.90%)
Metabolic and nutritional disorders 11 ( 6.90%)
Endocrine disorders 5 ( 3.14%)
![Page 17: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/17.jpg)
17
www.tfda.or.tz
Reports of Suspected ADRs from ARVs (June 06, to Nov 2009) SOC as per Vigiflow analysis cont…..
Cardiovascular disorders, general 1 (0.63%)
Heart rate and rhythm disorders 2 (1.25%)
Respiratory system disorders 5 ( 3.14%)
Platelet, bleeding & clotting disorders 1 (0.63%)
Urinary system disorders 1 (0.63%)
Reproductive disorders, female 5 ( 3.14%)
Body as a whole - general disorders 11 ( 6.90%)
Total 159 ( 100%)
This was almost 50% of all suspected reported cases of ADRs (2006/09)
![Page 18: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/18.jpg)
18
www.tfda.or.tz
Current development cont……..
• CEM of antimalarial already introduced and started this year 2009.
• Proposal for CEM of ARVs was approved and awaiting funds to start.
• Recruiting additional staff in the department
• Staff trainings in using Vigiflow and CEMflow was conducted
![Page 19: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/19.jpg)
19
www.tfda.or.tz
Future plans
• Introducing CEM of ARVs
• Introducing a Pregnancy Register
• Recruit additional staff at National PV centre
• Continue with CEM of antimalarial
• Collaboration with AIDS Relief/CRS, MSH and INESS
![Page 20: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/20.jpg)
20
www.tfda.or.tz
Challenges:
• Underreporting
• Funding for active surveillances
• Work load to HCW working in PHPs
• Human resources at the National and Zonal PV Centres.
• Making PV an integral part of care
![Page 21: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/21.jpg)
21
www.tfda.or.tz
CONCLUSION• The success of Pharmacovigilance is largely dependent
on the participation of all health care professionals countrywide to report ADRs / or AEs.
• Raising awareness and sensitization of on ADR / or AEs reporting to consumers can also contribute to improve reporting rate.
• PV is essential tool to promote the rational and safe use of medicines and the acceptability of mass treatment programmes.
![Page 22: Www.tfda.or.tz 1 Training Course for Introducing Pharmacovigilance of HIV Medicines: November 23-28 at the White Sands Hotel, Dar es Salaam, Tanzania.](https://reader036.fdocuments.in/reader036/viewer/2022062519/5697c01a1a28abf838ccebec/html5/thumbnails/22.jpg)
22
www.tfda.or.tz
Merci beaucoupMerci beaucoup !! Obrigado
Ahsanteni Sana
Mt. Kilimanjaro in Tanzania